Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

This study is testing a new targeted drug called HS-10375 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) that carries a specific genetic change (EGFR C797S mutation). This mutation often develops after treatment with earlier targeted therapies and can make those treatments stop working. **You may be eligible if:** - You are 18 or older - You have locally advanced or metastatic NSCLC that has stopped responding to prior treatments - You are in generally good physical condition (ECOG score 0–1) - You have at least one measurable tumor on scans - Your life expectancy is at least 12 weeks **You may NOT be eligible if:** - Your cancer does not have the specific EGFR mutation tested in this study - Your overall health or organ function falls below required thresholds - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.